XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Jan. 15, 2020
Sep. 30, 2021
Sep. 30, 2020
Condensed Consolidated Statements of Cash Flows      
Financial Designation, Predecessor and Successor [Fixed List] Predecessor Successor Successor
Cash flows from operating activities      
Net income(loss) $ (421) $ (11,441) $ (32,271)
Adjustments to reconcile net loss to net cash used in operating activities      
Depreciation, amortization, and accretion 368 16,620 13,666
Net loss on disposal of property and equipment   639 442
Share based compensation 13 5,293 695
Relief of contingent consideration     (3,978)
Interest on note payable, related party   1,926 812
Change in fair value of earnout liability   (3,695)  
Change in fair value of warrant liability   (45,946)  
Other   454  
Changes in operating assets and liabilities      
Accounts receivable, net 33 (3,505) 95
Receivables from related parties (333) (71)  
Prepaid expenses and other current and noncurrent assets (46) (5,188) 288
Accounts payable 315 (204) (413)
Payables to related parties (1) 458 112
Accrued liabilities (248) 2,321 1,083
Deferred revenue (37) 20,943 (384)
Customer deposits 13 4,641 (207)
Other current and noncurrent liabilities   (1,042) 142
Net cash used in operating activities (344) (17,797) (19,918)
Cash flows from investing activities      
Purchases of property, equipment and software (166) (39,679) (11,769)
Acquisition of business, net of cash received   (22,762)  
Net cash used in investing activities (166) (62,441) (11,769)
Cash flows from financing activities      
Proceeds from CRIS Business Combination   601,579  
Proceeds from note payable, related party   24,000 27,750
Payments on note payable, related party   (5,500)  
Capital-build funding, net   1,516 4,335
Payment of transaction costs for CRIS Business Combination   (28,143)  
Contributions     5,316
Net cash provided by financing activities   593,452 37,401
Net increase (decrease) in cash and restricted cash (510) 513,214 5,714
Cash and restricted cash, beginning of period 1,403 7,914 893
Beginning successor     257
Ending successor 257   5,971
Cash and restricted cash, end of period 893 521,128  
Supplemental disclosure of noncash investing and financing activities      
Accrued transaction costs for CRIS Business Combination   300  
Asset retirement obligations incurred   1,671 900
Non-cash increase in accounts receivable, capital-build, and capital-build liability   4,228 7,529
Reclassification of contingent earnout liability to equity upon triggering event   10,853  
Purchases of property and equipment in accounts payable and accrued liabilities $ 1,759 10,848 $ 2,366
Contingent earnout liability recognized upon the closing of the CRIS Business Combination   18,278  
Conversion of note payable, related party, to equity   59,590  
Reclassification of noncontrolling interest on Closing Date   436,739  
Fair value adjustment to noncontrolling interest   $ 1,141,037